Skip to main content

Table 2 Transplant outcomes in the intervention and control groups

From: ICT-based adherence monitoring in kidney transplant recipients: a randomized controlled trial

 

Intervention (n = 51)

Control (n = 54)

p value

Drug levels

 TAC trough level, ng/mL

5.3 ± 1.2

5.0 ± 1.2

0.282

 TAC CVa

23.9 ± 13.5

25.1 ± 11.4

0.645

 MPA trough level, μg/mL

2.8 ± 1.6

2.6 ± 1.3

0.600

 MPA CVa

37.9 ± 17.3

38.9 ± 19.4

0.783

eGFR

 4 weeks

67.8 ± 18.2

71.4 ± 21.8

0.365

 8 weeks

67.9 ± 19.7

71.3 ± 19.2

0.373

 12 weeks

66.7 ± 19.4

71.3 ± 21.6

0.262

 16 weeks

67.6 ± 17.4

72.4 ± 21.9

0.213

 20 weeks

66.3 ± 18.0

71.6 ± 21.8

0.182

 24 weeks

65.2 ± 18.9

70.2 ± 21.0

0.203

Number of events, n (%)

 De novo anti-HLA antibodies

3 (5.9)

8 (14.8)

0.135

 BK viremia

1 (2.0)

1 (1.9)

1.000

 BPAR

 

 DCGL

 
  1. Values are shown as mean ± standard deviation or number (%)
  2. BPAR Biopsy-proven acute rejection, CV Coefficient of variation, DCGL Death-censored graft loss, eGFR estimated glomerular filtration rate, HLA Human leukocyte antigen, MPA Mycophenolic acid, TAC Tacrolimus
  3. aCV = (standard deviation/mean) × 100%